Lv5
1450 积分 2024-03-08 加入
Site-specific construction of triptolide-based antibody-drug conjugates
23小时前
待确认
166 (PB154): A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs
2天前
已完结
Targeted degradation of membrane and extracellular proteins with LYTACs
5天前
已完结
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
10天前
已完结
Structure–Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist
16天前
已完结
Small Molecule‐Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs
18天前
已完结
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
22天前
已完结
Targeting ATR in patients with cancer
23天前
已完结
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
23天前
已完结
Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
23天前
已完结
皖公网安备34019202002308
